Abstract: Presented are novel apparatus and methods for protein characterization, identification, and sequencing using affinity capture laser desorption/ionization tandem mass spectrometry.

Abstract: Toothbrush comprising a handle (1) and a head (2), the handle (1) made out of a plastics material and having a general handle surface (3) and a grip portion (4), characterized in that the grip portion (4) comprises a projection (5) made out of said plastics material and which projects from the handle surface (3), said projection (5) having a gripping surface (6) which is raised from the handle surface (3) and has an elastomeric edge (7).

Abstract: Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.

Abstract: A toothbrush incorporating an indicator comprising a pressure indicating material which provides an optical signal without the provision of a power supply.

Abstract: A toothbrush incorporating an indicator comprising a pressure indicating material which provides an optical signal without the provision of a power supply. Preferably, the pressure sensitive material is a piezochromic material, such as a liquid crystal cholesterol ester.

Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.

Abstract: The present invention relates to an effervescent oral care composition with improved interproximal delivery properties. The composition comprises a first composition with about 2.5% by weight of an alkalimetal bicarbonate and a second composition with an acidic compound. Upon bringing the two compositions into contact with each other, e.g. by extruding them from a multicompartment container through a single outlet orifice, the alkalimetal bicarbonate and the acidic compound react with each other, causing an effervescent effect. By using 0.02% to less than 0.5% by weight, calculated on the total weight of the oral care composition, of the acidic compound, the interproximal delivery properties of the composition are significantly improved.

Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.

Abstract: A method and apparatus are disclosed for determining the boundaries of guard intervals of data symbols being received in a coded orthogonal frequency division multiplexed signal. Temporal samples separated by an interval of an active interval of a data symbol are associated in pairs, and difference signals obtained. The dispersion of a first comparison block of difference signals is determined, and compared to the dispersion of a second comparison block of difference signals, the second comparison block being displaced from the first comparison block by n samples. An F ratio is calculated for the dispersions of the two blocks. F ratios are iterated in a succession of comparison blocks, and a signal representing the F ratios subjected to peak detection. The peaks represent the boundaries of the symbol's guard interval. This information is utilized in synchronizing an FFT window for subsequent signal reconstruction.

Abstract: This invention relates to the preparation of novel 1-epi-aminoglycosides, useful as antibacterial agents, and also relates to the process for the preparation of known as well as novel 1-N-substituted aminoglycoside antibacterial agents.

Abstract: This invention relates to the preparation of novel 1-desamino-1-oxo-aminoglycosides and their use as intermediates in the preparation of novel 1-desamino-1-hydroxy and 1-desamino-1-epi-hydroxyaminoglycoside antibacterial agents.

Abstract: Aminoglycoside 66-40C, a minor product produced by the fermentation of Micromonospora inyoensis, is separated from said fermentation mixture, and is used as an intermediate in preparing the known antibiotic, sisomicin, as well as 6' -N-alkylsisomicins having antibacterial activity. Claimed are Aminoglycoside 66-40C as well as 6' -N-t-alkylsisomicins having a tertiary carbon bonded to the 6' -nitrogen.

Abstract: The novel aminoglycoside, 0-2-amino-2,3,4-trideoxy-.alpha.-D-glycero-hex-4-enopyranosyl-(1.fwdarw.4) -garamine, is prepared by treating Aminoglycoside 66-40C with aqueous acid followed by treatment with a hydride donor reducing agent. Pharmaceutical compositions of the novel aminoglycoside and its pharmaceutically acceptable acid addition salts are described as well as their use as antiprotozoal agents.